AlgoNomics’ vision is to employ its advanced proprietary platform in structural bioinformatics tools to develop rationally designed therapeutics in the broad field of immunotherapy.

AlgoNomics offers in silico support to companies that develop rationally designed vaccines and therapeutic proteins.

AlgoNomics owns a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains biologically validated, innovative tools, which have been developed in-house. These tools add great value in target characterization and lead optimization.

Business strategy

AlgoNomics is devoted to the discovery process of novel vaccines and therapeutic proteins. To this end, it applies its proprietary technology mainly in the field of peptides and antibodies, and in the development of prophylactic and therapeutic vaccines.

In order to realize its goals AlgoNomics:

• uses its Epibase® platform for the epitope profiling and Immunotuning® of therapeutic proteins and antibodies,
• uses its Epibase® platform for the identification of epitopes that increase the potency of vaccines,
• employs its Tripole® technology platform to identify, modify and improve therapeutic peptides and proteins

AlgoNomics offers its services to biopharmaceutical companies against fee-for-service payments and milestone fees.

Collaborations with biopharmaceutical companies and academic organisations are central to our business strategy.